Therapy Acceleration Program
How to Apply
Therapy Acceleration Program
How to Apply
TAP accepts and reviews partnering inquiries year round.
TAP collaborates with and makes equity investments in biotech companies to support the development of novel platforms, first-in-class assets addressing high unmet medical needs, emerging patient populations and orphan indications.
- Click here to download the initial inquiry form
Send the completed inquiry form and non-confidential presentation to Dr. Jun Xu, Executive Director - TAP Lead, Therapy Acceleration Program® (jun.xu@lls.org)
Want to know more about TAP, please download a presentation and a one-pager for more information.
How did TAP impact the development of Elzonris?
LLS awarded several grants to Dr. Arthur Frankel between 1998-2008 to develop fusion protein therapies for blood cancers, including SL-401 (now known as Elzonris). TAP then partnered with Stemline Therapeutics in 2013 to support key clinical studies for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Listen to what Dr. Arthur Frankel and Peter MacDonald, SVP of Corporate & Business Development of Stemline Therapeutics, have to say about LLS, the role TAP played in the development of Elzonris and the value TAP created for Stemline beyond the funding amount.
Elzonris® is the first approved therapy for blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare blood cancer.
Due Diligence Process
Each year, TAP reviews opportunities from approximately 80-100 biotech companies to identify those with the highest potential to change the standard of care. Funding only the most promising projects that have a clear path forward for patients, TAP only invests in several new projects annually, with an open partnering cycle all year long.
Diligence typically takes 3-6 months, but varies based on company responsiveness to LLS requests.
